Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of methylprednisolone and "ASTED." Methylprednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It acts by binding to the glucocorticoid receptor, modulating gene expression, and suppressing the immune response. Methylprednisolone is used in a wide range of conditions including allergic reactions, autoimmune diseases, asthma exacerbations, arthritis, and other inflammatory or immune-mediated disorders[4][6][8]. The mechanism of action involves inhibition of leukocyte infiltration at the site of inflammation, interference with mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue formation. The identity or pharmacological nature of "ASTED" could not be determined from available sources; it does not correspond to any recognized pharmaceutical ingredient or established abbreviation in drug databases as of June 2025. Therefore, no information about its mechanism(s), class(es), developer(s), manufacturer(s), or clinical use can be provided.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylprednisolone + ASTED.